Senzime receives research grants from Green Innovation Park
Uppsala, 19 May 2017. Senzime (publ) receives research grant from Green Innovation Park (GIP). This collaborative study is aimed at evaluating the usability of OnZurf Probe to monitor dispersion of various substances in soil. The study will be conducted at Swedish University of Agricultural Sciences ( SLU) in Umeå, as a collaboration between Senzime and researchers in the Department of Forest Ecology and Care. The grant of 50,000 SEK allows the company to expand the market opportunities for OnZurf Probe to include ecologic monitoring.
There is a need to measure the presence of certain substances (such as carbon and nitrogen compounds) in the roots of trees. Roots secrete various compounds that are substrates for microorganisms. In order to monitor the secretion of substances from tree roots, a sample collector must be able to be positioned in close proximity to the target root system, and must avoid sampling of the surrounding environment that may contaminate the results. Senzime’s OnZurf Probe has an "open window" that allows to direct the probe precisely to the measuring area of interest, thus collecting substances from the target area. It is anticipated that the results will be presented by the end of 2017. Senzime’s main focus of monitoring development remains in the medical technology area where the company is expecting the CE marking.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on NASDAQ First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com